Identification of HLA-A2- And A24-restricted T-cell epitopes derived from SOX6 expressed in glioma stem cells for immunotherapy

Ryo Ueda, Kozo Ohkusu-Tsukada, Noemi Fusaki, Akio Soeda, Takeshi Kawase, Yutaka Kawakami, Masahiro Toda

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Malignant gliomas are the most aggressive human primary brain tumors and are currently incurable. Immunotherapies have the potential to target glioma and glioma stem cells (GSCs) that are resistant to conventional therapies. We previously identified SOX6 as a human glioma antigen and demonstrated that vaccination with SOX6 DNA induced cytotoxic T lymphocytes (CTLs) specific for glioma, thereby exerting therapeutic antitumor responses in glioma-bearing mice. In this study, we attempted to identify SOX6-derived peptides as specific targets for effective and safe T-cell-mediated immunotherapy targeting SOX6-positive glioma and GSCs. In vitro stimulation with human leukocyte antigen (HLA)-A*2402 (A24)-restricted peptides, RFENLGPQL (SOX6504) and PYYEEQARL (SOX6628) or the HLA-A*0201 (A2)-restricted peptide, ALFGDQDTV (SOX6447) was capable of inducing SOX6 peptide-specific CTLs in peripheral blood mononuclear cells derived from healthy donors and glioma patients. These CTLs were able to lyse a majority of glioma cell lines and a GSC line derived from human glioblastoma in an HLA Class I-restricted and an antigen-dependent manner. Furthermore, peptide vaccines of SOX6628, which was conserved in the murine SOX6 protein and expected to bind to major histocompatibility complex (MHC) H-2d, induced CTLs specific for SOX6628 in H-2d mice. Normal autologous cells from mice, in which SOX6-specific immune responses were generated, were not destroyed. These results suggest that these SOX6 peptides are potnetially immunogenic in HLA-A24 or -A2 positive glioma patients and should be considered as a promising strategy for safe and effective T-cell-based immunotherapy of patients with gliomas.

Original languageEnglish
Pages (from-to)919-929
Number of pages11
JournalInternational Journal of Cancer
Volume126
Issue number4
DOIs
Publication statusPublished - 2010 Feb 15

Fingerprint

T-Lymphocyte Epitopes
HLA Antigens
varespladib methyl
Glioma
Immunotherapy
Stem Cells
Cytotoxic T-Lymphocytes
Peptides
T-Lymphocytes
Cell Line
Histocompatibility Antigens Class I
Subunit Vaccines
Glioblastoma
Major Histocompatibility Complex
Brain Neoplasms
Blood Cells
Vaccination

Keywords

  • CTL epitope
  • Glioma stem cells
  • Immunotherapy
  • SOX6
  • Tumor antigen

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Identification of HLA-A2- And A24-restricted T-cell epitopes derived from SOX6 expressed in glioma stem cells for immunotherapy. / Ueda, Ryo; Ohkusu-Tsukada, Kozo; Fusaki, Noemi; Soeda, Akio; Kawase, Takeshi; Kawakami, Yutaka; Toda, Masahiro.

In: International Journal of Cancer, Vol. 126, No. 4, 15.02.2010, p. 919-929.

Research output: Contribution to journalArticle

Ueda, Ryo ; Ohkusu-Tsukada, Kozo ; Fusaki, Noemi ; Soeda, Akio ; Kawase, Takeshi ; Kawakami, Yutaka ; Toda, Masahiro. / Identification of HLA-A2- And A24-restricted T-cell epitopes derived from SOX6 expressed in glioma stem cells for immunotherapy. In: International Journal of Cancer. 2010 ; Vol. 126, No. 4. pp. 919-929.
@article{7e7e2dfa26ea4810a9380a9c54f638ce,
title = "Identification of HLA-A2- And A24-restricted T-cell epitopes derived from SOX6 expressed in glioma stem cells for immunotherapy",
abstract = "Malignant gliomas are the most aggressive human primary brain tumors and are currently incurable. Immunotherapies have the potential to target glioma and glioma stem cells (GSCs) that are resistant to conventional therapies. We previously identified SOX6 as a human glioma antigen and demonstrated that vaccination with SOX6 DNA induced cytotoxic T lymphocytes (CTLs) specific for glioma, thereby exerting therapeutic antitumor responses in glioma-bearing mice. In this study, we attempted to identify SOX6-derived peptides as specific targets for effective and safe T-cell-mediated immunotherapy targeting SOX6-positive glioma and GSCs. In vitro stimulation with human leukocyte antigen (HLA)-A*2402 (A24)-restricted peptides, RFENLGPQL (SOX6504) and PYYEEQARL (SOX6628) or the HLA-A*0201 (A2)-restricted peptide, ALFGDQDTV (SOX6447) was capable of inducing SOX6 peptide-specific CTLs in peripheral blood mononuclear cells derived from healthy donors and glioma patients. These CTLs were able to lyse a majority of glioma cell lines and a GSC line derived from human glioblastoma in an HLA Class I-restricted and an antigen-dependent manner. Furthermore, peptide vaccines of SOX6628, which was conserved in the murine SOX6 protein and expected to bind to major histocompatibility complex (MHC) H-2d, induced CTLs specific for SOX6628 in H-2d mice. Normal autologous cells from mice, in which SOX6-specific immune responses were generated, were not destroyed. These results suggest that these SOX6 peptides are potnetially immunogenic in HLA-A24 or -A2 positive glioma patients and should be considered as a promising strategy for safe and effective T-cell-based immunotherapy of patients with gliomas.",
keywords = "CTL epitope, Glioma stem cells, Immunotherapy, SOX6, Tumor antigen",
author = "Ryo Ueda and Kozo Ohkusu-Tsukada and Noemi Fusaki and Akio Soeda and Takeshi Kawase and Yutaka Kawakami and Masahiro Toda",
year = "2010",
month = "2",
day = "15",
doi = "10.1002/ijc.24851",
language = "English",
volume = "126",
pages = "919--929",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "4",

}

TY - JOUR

T1 - Identification of HLA-A2- And A24-restricted T-cell epitopes derived from SOX6 expressed in glioma stem cells for immunotherapy

AU - Ueda, Ryo

AU - Ohkusu-Tsukada, Kozo

AU - Fusaki, Noemi

AU - Soeda, Akio

AU - Kawase, Takeshi

AU - Kawakami, Yutaka

AU - Toda, Masahiro

PY - 2010/2/15

Y1 - 2010/2/15

N2 - Malignant gliomas are the most aggressive human primary brain tumors and are currently incurable. Immunotherapies have the potential to target glioma and glioma stem cells (GSCs) that are resistant to conventional therapies. We previously identified SOX6 as a human glioma antigen and demonstrated that vaccination with SOX6 DNA induced cytotoxic T lymphocytes (CTLs) specific for glioma, thereby exerting therapeutic antitumor responses in glioma-bearing mice. In this study, we attempted to identify SOX6-derived peptides as specific targets for effective and safe T-cell-mediated immunotherapy targeting SOX6-positive glioma and GSCs. In vitro stimulation with human leukocyte antigen (HLA)-A*2402 (A24)-restricted peptides, RFENLGPQL (SOX6504) and PYYEEQARL (SOX6628) or the HLA-A*0201 (A2)-restricted peptide, ALFGDQDTV (SOX6447) was capable of inducing SOX6 peptide-specific CTLs in peripheral blood mononuclear cells derived from healthy donors and glioma patients. These CTLs were able to lyse a majority of glioma cell lines and a GSC line derived from human glioblastoma in an HLA Class I-restricted and an antigen-dependent manner. Furthermore, peptide vaccines of SOX6628, which was conserved in the murine SOX6 protein and expected to bind to major histocompatibility complex (MHC) H-2d, induced CTLs specific for SOX6628 in H-2d mice. Normal autologous cells from mice, in which SOX6-specific immune responses were generated, were not destroyed. These results suggest that these SOX6 peptides are potnetially immunogenic in HLA-A24 or -A2 positive glioma patients and should be considered as a promising strategy for safe and effective T-cell-based immunotherapy of patients with gliomas.

AB - Malignant gliomas are the most aggressive human primary brain tumors and are currently incurable. Immunotherapies have the potential to target glioma and glioma stem cells (GSCs) that are resistant to conventional therapies. We previously identified SOX6 as a human glioma antigen and demonstrated that vaccination with SOX6 DNA induced cytotoxic T lymphocytes (CTLs) specific for glioma, thereby exerting therapeutic antitumor responses in glioma-bearing mice. In this study, we attempted to identify SOX6-derived peptides as specific targets for effective and safe T-cell-mediated immunotherapy targeting SOX6-positive glioma and GSCs. In vitro stimulation with human leukocyte antigen (HLA)-A*2402 (A24)-restricted peptides, RFENLGPQL (SOX6504) and PYYEEQARL (SOX6628) or the HLA-A*0201 (A2)-restricted peptide, ALFGDQDTV (SOX6447) was capable of inducing SOX6 peptide-specific CTLs in peripheral blood mononuclear cells derived from healthy donors and glioma patients. These CTLs were able to lyse a majority of glioma cell lines and a GSC line derived from human glioblastoma in an HLA Class I-restricted and an antigen-dependent manner. Furthermore, peptide vaccines of SOX6628, which was conserved in the murine SOX6 protein and expected to bind to major histocompatibility complex (MHC) H-2d, induced CTLs specific for SOX6628 in H-2d mice. Normal autologous cells from mice, in which SOX6-specific immune responses were generated, were not destroyed. These results suggest that these SOX6 peptides are potnetially immunogenic in HLA-A24 or -A2 positive glioma patients and should be considered as a promising strategy for safe and effective T-cell-based immunotherapy of patients with gliomas.

KW - CTL epitope

KW - Glioma stem cells

KW - Immunotherapy

KW - SOX6

KW - Tumor antigen

UR - http://www.scopus.com/inward/record.url?scp=74049105516&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=74049105516&partnerID=8YFLogxK

U2 - 10.1002/ijc.24851

DO - 10.1002/ijc.24851

M3 - Article

C2 - 19728337

AN - SCOPUS:74049105516

VL - 126

SP - 919

EP - 929

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 4

ER -